NEJM January 8, 2026

A recent clinical study investigated the effectiveness of evolocumab, a PCSK9 inhibitor, in preventing major cardiovascular events for individuals who have never suffered a heart attack or stroke. Researchers conducted a massive trial involving over 12,000 participants with underlying conditions like diabetes or atherosclerosis to see if the medication could lower their initial risk. The results demonstrated that patients receiving the drug experienced significantly fewer life-threatening incidents and arterial procedures compared to those who took a placebo. Over a follow-up period of nearly five years, the treatment proved both statistically effective and safe for primary prevention. These findings suggest that the medication provides a vital protective benefit for high-risk patients before a first major cardiac event occurs. This evidence expands the known clinical utility of the drug beyond just treating patients with a history of vascular disease.